UnitedHealth stock (UNH) has had a volatile run, rising 2.2% over the past week but falling 4.5% in the last month and a steep 46.2% over the past year. Despite this turbulence, Wall Street’s analysts are strongly bullish, with a consensus rating of Strong Buy and a 12‑month average price target of $366.47 versus a last close of $273.98.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
This consensus target suggests meaningful upside potential as the market reassesses the company’s earnings power and valuation. Analysts see room for recovery as the stock trades well below its historical multiples, even while the core business and growth engines like Optum Health and technology initiatives remain in place.
Analyst John Ransom of Raymond James recently upgraded UnitedHealth from Market Perform to Buy on April 1, 2026, setting a $330 price target, implying solid upside from current levels. Ransom, ranked 833 out of 12,068 analysts on TipRanks with a 57.55% success rate and an 8.4% average return per rating, views the recent selloff as a compelling entry point.
Ransom’s bullish case centers on the company’s push into AI to lower general and administrative costs, along with improving margins in Optum Health as weaker clinics are shuttered and higher-margin segments are optimized. He forecasts gradual G&A efficiency and better risk and fee‑for‑service margins, which lift his 2027–2028 EPS estimates by roughly 7.5%–8% versus prior forecasts and support an Outperform rating.
Based on his new numbers, UnitedHealth now trades at about 12.7 times his 2027 EPS estimate and 10.6 times 2028, a discount to its historical ~20x multiple and closer to peers, with his $330 target implying around 13x 2028 EPS. Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.